Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a webcast interview on April 23, 2021, at 8:30 AM Eastern, featuring CEO Lisa Conte, aimed at providing an overview of Napo EU S.p.A., its Italian subsidiary. The company has also launched a rebranded Napo EU website, showcasing a new logo and promising expanded content. Mytesi®, Jaguar's key product, is the only FDA-approved plant-based medication for noninfectious diarrhea in adults with HIV/AIDS. The company focuses on developing sustainable plant-based pharmaceuticals for gastrointestinal issues.
Jaguar Health (NASDAQ:JAGX) announced an upsizing of its at-the-market (ATM) financing program by $15.3 million on April 15, 2021. This increase aims to provide future funding, with the company stating it does not plan to issue shares immediately. The company is pursuing conditional marketing authorization for crofelemer for COVID-related diarrhea. Additionally, Jaguar is merging Napo EU with the Dragon SPAC, anticipated for mid-2021, which is expected to support clinical efforts related to diarrhea in cancer patients. An educational contest is also launching for HIV awareness.
Jaguar Health (NASDAQ:JAGX) announces the acceptance of an abstract related to cancer therapy-related diarrhea (CTD) for poster presentation at the 2021 ASCO Annual Meeting, scheduled for June 4-8, 2021. This abstract is from Napo Pharmaceuticals, a subsidiary of Jaguar. In total, three CTD-related abstracts have been accepted for the event. The ASCO meeting received over 5,400 submissions this year. The press release highlights the significance of addressing CTD, a common side effect of cancer therapies that can impact treatment adherence and patient outcomes.
Jaguar Health (NASDAQ:JAGX) announced an amendment to its equity purchase agreement with Oasis Capital, increasing the stock purchase price from $0.436 to $3.00 per share. This amendment allows Oasis to purchase up to $2.0 million of Jaguar common stock over a 36-month period. The new price reflects the stock's recent performance, providing Jaguar access to capital for working needs while focusing on becoming a cash flow positive business through its product, Mytesi. The company will also issue a warrant for 100,000 common shares to Oasis as part of this agreement.
Jaguar Health, Inc. (NASDAQ:JAGX) has promoted Carol Lizak to the role of chief financial officer. This decision reflects her significant contributions in finance and strategic planning since joining the company in May 2019. Lizak brings over 20 years of experience in financial roles across various companies, enhancing Jaguar's transition from an R&D focus to a commercial-stage entity. Jaguar specializes in plant-based, non-opioid medicines for gastrointestinal issues and is known for its Mytesi® product, which is FDA-approved for treating noninfectious diarrhea in adults with HIV/AIDS.
Jaguar Health, Inc. (NASDAQ:JAGX) announced employee inducement grants on March 26, 2021, allocating nonstatutory stock options totaling 2,000 to 35,000 shares to five new employees. The exercise price is set at $1.84 per share, reflecting the March 26 closing price. Vesting occurs over three years, with the first 25% vesting nine months post-hire. Grants were made to attract talent as per NASDAQ rules. Jaguar develops plant-based medicines focused on gastrointestinal conditions, notably offering Mytesi, an FDA-approved product for HIV/AIDS patients.
Jaguar Health reported strong financial results for 2020, with Mytesi net sales rising 64% to approximately $9.3 million and gross sales increasing 148% to around $20.4 million. Despite a 7% decline in total Mytesi unit sales volume, the company saw a 12% reduction in net loss, totaling $33.8 million. Operating expenses grew by 4% year-over-year, primarily due to a rise in inducement expenses. Jaguar's focus on R&D remains evident with expenses of $6.4 million, reflecting ongoing development of Mytesi indications.
Jaguar Health, Inc. (NASDAQ:JAGX) has announced its support for the selection of the investment bank and nominated advisor for the proposed merger of the Dragon SPAC with its Italian subsidiary, Napo EU. This merger is anticipated to list on AIM Italia. Additionally, Jaguar's subsidiary conducted a meeting with the EU regulatory authority regarding crofelemer for COVID-related diarrhea, indicating the presence of unmet medical needs in this domain. Regulatory approval would allow for a conditional marketing authorization, utilizing safety data from Napo's approved US NDA.
Jaguar Health has incorporated its subsidiary, Napo EU, in Italy to combat inflammatory diarrhea linked to long-hauler syndrome post-COVID-19, primarily in Europe. The subsidiary is the target of a forthcoming merger with the Dragon SPAC, expected to list on AIM Italia. CEO Lisa Conte announced the search for key management roles and ongoing regulatory efforts to gain conditional marketing authorization from the European Medicines Agency (EMA).
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
